Index A AACR (American Association for Cancer Research), 1–3, 8, 11, 156–57, 166–68, 193, 196–97 Alexis Browning, 7, 87, 108, 112 AML (Acute myeloid leukemia), 16, 31, 91, 94–95, 193 Angiogenesis, 32–33, 184, 193 Antibody–drug conjugates, 28, 167 Artificial intelligence, 5, 11, 65–66, 69, 76, 143–44, 146–47, 174, 184, 187, 193 ASPS (alveolar soft part sarcoma), 7, 77, 106, 108, 111, 113, 193 AYAs (Adolescents and Young Adults), 17, 37, 68, 78, 108, 132, 134–37, 178, 193 B Basic research, 1, 20, 24, 27, 29, 100, 193 Biomarkers, 1, 69, 71, 85, 89, 103, 105, 125–26, 131, 147, 150, 184 Bispecific antibody, 14, 77, 127, 184, 192–93 Bladder cancer, 7, 10–11, 18, 36, 42, 44, 48, 104, 107–8, 117, 119–20, 192–93 Breast cancer, 11–12, 20, 22, 26, 51–54, 56, 58, 60–62, 77–78, 86, 138–39, 184, 186, 188, 192–93 Breast cancer screening, 5, 11, 59, 61, 63, 141, 193 Breastfeeding, 52–53, 193 Brian Beck, 6, 91–92 C Cachexia, 133–34, 138, 184, 193 Cancer, bile duct, 6, 87, 107, 192 Cancer care, 5–6, 15, 18, 22, 75, 79, 81, 130–31, 135, 141, 186, 189 Cancer detection, 5, 11, 54, 65–66, 81 Cancer development, 4–6, 21, 24–54, 68–69, 83, 99, 128, 148, 158, 163, 193–94 Cancer diagnosis, 3, 5, 7, 36, 38, 66, 78, 80, 82, 132–33, 135–40, 159, 161 Cancer disparities, 8, 15, 17–19, 163, 193 Cancer immunotherapy, 1, 6–7, 99, 105, 108, 125, 128–29, 144, 166, 193 Cancer patients, 1–2, 7, 88–89, 132, 135, 141–42, 147, 182, 185, 188, 193, 196 Cancer prevention, 1, 3, 8–9, 12, 20, 22, 64, 144, 146, 150, 153–54, 161, 167 Cancer recurrence, 80, 82, 125, 128, 134, 137–38, 146, 193 Cancer research, 8–9, 12, 111, 114–15, 143–45, 147, 150, 152–54, 158, 161, 165–67, 193, 196–97 Cancer risk, 5, 38, 43, 45–47, 51–52, 171–72, 193 Cancer risk factors, 5, 21, 38, 61 Cancer screening, 5, 8, 21, 27, 54–55, 57–65, 67, 152–53, 158–59, 161, 163, 165, 167 Cancer screening guidelines, 59–60, 62, 64, 193 Cancer screening tests, 54, 57–58, 65, 67, 193 Cancer survivors, 1, 7–8, 12, 125, 132–36, 138–41, 143, 153, 157, 166–67, 193, 197 Cancer syndromes, hereditary, 61, 146, 194 Cancer therapies, 103–5, 133, 136, 144–45, 151, 156–57 Cancer treatment, 6–8, 15, 17, 35–36, 72–74, 76, 78–82, 99–100, 115–16, 128–29, 131–35, 137–39, 150–51, 153, 193–94 Caregivers, 7, 13, 132, 135–36, 138–39, 141–42, 179, 185, 189, 193, 196 Cayden Addison, 7, 115 Cell therapies, 7, 116, 158, 167 Cervical cancer, 21–22, 38, 48, 50, 56, 58, 60, 62, 159, 185, 187 Cervical cancer screening, 21, 58, 63–64, 153, 158–59, 193 Checkpoint inhibitors, 7, 102–3, 108, 128, 133 Chemotherapy, 76–77, 80, 82–84, 89, 91, 93, 104–5, 107–8, 115, 123, 126–27, 131, 148–50, 184–85, 192–93 Childhood cancers, 37, 90, 136, 162, 193 Childhood cancer survivors, 18, 136, 162 Cindy Brown, 7, 121 Clinical research, 1, 27, 68, 70, 90, 97, 102–3, 109, 119, 125, 158 Clinical studies, 8, 20, 25, 27, 65, 67–69, 72, 80, 84, 95, 107–8 Clinical trials, 7–8, 27, 68–74, 77–80, 84–86, 90–95, 102–3, 105, 107–9, 111, 113, 119, 121–24, 127, 129–31, 142, 144, 148, 155–57, 165–66 Colbert English, 96, 98 Collaborations, 12, 52, 67, 153, 156, 158, 196 Colon cancer, 10, 52, 65, 84, 93, 191, 193 Colonoscopy, 55–57, 63, 65–67, 93, 185, 193 Colorectal cancer, 3, 6, 20–22, 42, 44, 55–56, 59–60, 75, 77, 90–91, 93, 151, 153, 185, 192–93 early-onset, 20–21, 41 Colorectal cancer screening, 21, 63–64, 173, 182, 193 CPSTF (Community Preventive Services Task Force), 64, 141, 174, 193 Cytokine release syndrome (CRS), 121, 125–26, 185 D DLBCL (Diffuse large B-cell lymphoma), 94, 121, 124 Drug development, 8, 25, 32, 83, 105, 155, 193 E Early detection, 1, 3, 5–6, 8, 11–12, 15, 19–21, 25, 54–67, 144, 146, 150, 152–53 E-cigarettes, 8, 40–41, 159, 167, 170, 186, 193 Epigenome, 32, 34–36, 77, 136, 186, 192–93 Index AACR Cancer Progress Report 2023 193
RkJQdWJsaXNoZXIy NTkzMzk=